Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Silence On OTC Singulair Speaks Volumes On Switch Outlook

This article was originally published in The Tan Sheet

Executive Summary

Merck & Co.’s silence on an OTC version of Singulair is a sign of the relatively “quiet” 2015 switch market despite the call for novel switches, particularly to treat chronic conditions, from FDA’s Nonprescription Drug Safe Use Regulatory Expansion Initiative.

Advertisement

Related Content

OTC Switch Interest Cooled By Study Costs To Update Safety Data
Dry Powder Blows Dr. Natural OTC Epinephrine Inhaler Out Of Compliance
Galderma Acne Ingredient Rx-to-OTC Switch Headed For NDAC In April
Galderma Acne Ingredient Switch Receives NDAC Review In April
Galderma Acne Ingredient Switch Receives NDAC Review In April
Perrigo OTC Switch Kit Features Rx Generics As Handy Tool
First-In-Class Nasacort OTC Also Originates ‘Children’s’ Label
CAGR For OTC Switch Forecast At 5%, But Without Statins, Asthma Treatments
Chronic Conditions Data Emphasize Need For Additional, Innovative OTCs
Adulturated red yeast rice

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS108075

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel